GYNECOLOGIC CANCERS

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.

Based on OS data from the phase 3 ENGOT-OV16/NOVA trial, the FDA has requested niraparib to have restricted use as a second-line maintenance therapy for patients without germline BRCA mutations.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.

Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.

With 30 months additional follow-up on the EMPOWER-Cervical 1 trial, cemiplimab monotherapy showed efficacy in patients with metastatic cervical cancer.

Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.

Mature survival data from the phase 3 ICON8 trial revealed no significant difference between administering weekly dose-dense chemotherapy and standard 3-weekly chemotherapy as front-line therapy for patients with epithelial ovarian cancer.

Shana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.

Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.

The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.

Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.

The benefit of pembrolizumab compared with placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent is under evaluation in the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

The phase 2 VB C-02 trial examining VB10.16 in combination with atezolizumab demonstrated positive results in patients with HPV16-positive advanced cervical cancer.

The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.

Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

High risk human papillomavirus infection appears to be a strong determinant of cervical cancer prognosis over 15 years after diagnosis.

The phase 1a/b NEBULA trial is investigating the safety and preliminary efficacy of the adenoviral vector NG-641 in combination with nivolumab in patients with previously treated metastatic or advanced epithelial tumors.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

A survival benefit has been shown in a phase 2 study using intermittent relacorilant and nab-paclitaxel for the treatment of patients with recurrent, platinum-resistant ovarian cancer.

The phase 3 ATHENA-MONO trial meet it primary end point of improvement in progression-free survival with rucaparib in patients with newly-diagnosed, advanced ovarian cancer.